Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine
JOURNAL OF RHEUMATOLOGY, vol.38, no.3, pp.516-518, 2011 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 38 Issue: 3
- Publication Date: 2011
- Doi Number: 10.3899/jrheum.100718
- Journal Name: JOURNAL OF RHEUMATOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.516-518
- Keywords: FAMILIAL MEDITERRANEAN FEV, ANAKINRA, RESISTANT, ETANERCEPT, ANAKINRA, CHILDREN, PROTEIN, PYRIN
- Istanbul University Affiliated: No
Abstract
Objective. Familial Mediterranean fever (FMF) is a recessively inherited autoinflammatory disorder characterized by recurrent attacks of fever and serositis. Although colchicine is the standard therapy for preventing attacks and suppressing inflammation, 5%-10% of compliant patients are colchicine-resistant. We report the effect of anti-tumor necrosis factor therapy (etanercept) and anti-interleukin 1 (IL-1) treatment (anakinra) in 6 cases resistant to colchicine therapy.